The Heather Cutler Foundation

This account is verified. Learn more

@TeamHeatherNL

Atlantic Canada’s trusted voice for pancreatic cancer. Supporting Canadians living with pancreatic cancer, caregivers, and advancing research & care.

Mount Pearl, Newfoundland heathercutler.ca Joined June 2024

396 Following 99 Followers 834 Posts

Latest posts 5

The Heather Cutler Foundation @TeamHeatherNL 2d

New: a free directory of pancreatic cancer clinical trials with sites in Canada. 59 studies today, refreshed daily from ClinicalTrials.gov. Filter by province, status, and phase. No sign-in needed.
trials.heathercutler.ca
#PancreaticCancer #WeAreCanadaToo

Purple graphic with the headline "Find pancreatic cancer trials in Canada" and the web address trials.heathercutler.ca. Text reads: "Browse pancreatic cancer studies with locations in Canada. Sort by status, location, and phase, and bring better questions to your care team." On the right, a phone screen shows the trial finder, with a search bar, an "All Canada" location filter, an "Accepting participants" filter, and a count of 59 studies, including a Phase 2 study listed as accepting participants in Toronto. At the bottom: "The Heather Cutler Foundation" and "First build. Tell us what to improve."

The Heather Cutler Foundation @TeamHeatherNL 4d

We asked Revolution Medicines how Canadians can get Rasonque (Daraxonrasib). Its answer: a paid, doctor-led route, no guarantee of supply, and no filing date for Canada. The reply, in full: heathercutler.ca/revolution-med…

heathercutler.ca Revolution Medicines responds to questions about Rasonque pricing and access in Canada Revolution Medicines confirmed its named-patient route for Rasonque is paid and gave no Canada filing date. What it said, and what remains unanswered.

The Heather Cutler Foundation @TeamHeatherNL Nov 3

Not filed in Canada. Not affordable from the U.S. Canadian oncologists are naming the result: a breakthrough treatment becoming an unfulfilled promise.

Common Sense Oncology Verified account @csoncol Nov 2

CSO and oncologists across Canada are speaking out about escalating cancer drug costs after the recent U.S. pricing announcement for the new pancreatic cancer drug daraxonrasib. The list price of CAD$56,300 per month means it will be inaccessible to many patients and health systems, and risks turning a breakthrough treatment into an unfulfilled promise to cancer patients.

Watch the segment on daraxonrasib from CBC's The National for more: tinyurl.com/aaecm4nv

#CommonSenseOncology #CancerCare
View quoted post on X

The Heather Cutler Foundation @TeamHeatherNL Oct 31

Our new website is live. 💜
Plain-language guides, a caregiver hub, financial support (including our $500 Port to Care grant), and a new report card on Canada’s response to pancreatic cancer.

Desktop computer monitor on a wooden desk showing the new Heather Cutler Foundation website homepage. The headline reads "Better care. Fewer barriers." beside a smiling photo of Heather Cutler, captioned "A nurse, a mother, and the reason the foundation began."

The Heather Cutler Foundation @TeamHeatherNL Oct 26

A second Daraxonrasib trial is now recruiting in Canada. RASolute 304 is for people who've had surgery to remove pancreatic cancer — recruiting at Princess Margaret (Toronto) and McGill University Health Centre (Montreal) heathercutler.ca/is-daraxonrasi…

heathercutler.ca Is Daraxonrasib Available in Canada? Explore daraxonrasib access for pancreatic cancer in Canada, including the distinction between approval, public funding, and clinical trial availability.